TRANSCODE THERAPEUTICS, INC. (RNAZ) Free cash flow 2021–2025
TRANSCODE THERAPEUTICS, INC. (RNAZ) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$19.5MFY2025 · since FY2021: -$5.5M → -$19.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$19.5M | -46.2% |
| FY2024 | -$13.4M | +26.2% |
| FY2023 | -$18.1M | -14.2% |
| FY2022 | -$15.9M | -187.3% |
| FY2021 | -$5.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAZ financial trends
RNAZ RevenueRNAZ Net incomeRNAZ Net marginRNAZ Gross profitRNAZ Gross marginRNAZ Operating incomeRNAZ Operating marginRNAZ Operating cash flowRNAZ Capital expendituresRNAZ Return on equityRNAZ Stock buybacksRNAZ Dividends paidRNAZ Total assetsRNAZ Total liabilitiesRNAZ Shareholders’ equityRNAZ overview →